{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:34:47Z","timestamp":1792136087760,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1253,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>This study assessed the potential pharmacokinetic interaction and safety\/tolerability of taranabant and phentermine coadministration. This was a randomized, double\u2010blind, 3\u2010panel, fixed\u2010sequence study in healthy participants. Panels A, B, and C evaluated the safety\/tolerability of phentermine 15 mg coadministered with taranabant 0.5, 1, and 2 mg for 7 days (panel A) and 28 days (panels B and C). In panels A and C, phentermine 15 mg was administered both with (7 days, panel A; 28 days, panel C) and without (7 days) taranabant 0.5 mg or 2 mg to evaluate pharmacokinetics. The primary endpoint was phentermine AUC<jats:sub>0\u201324 h<\/jats:sub>in panels A and C. Secondary endpoints were changes from baseline in blood pressure and heart rate for all panels. The geometric mean ratios and 90% confidence intervals for phentermine AUC<jats:sub>0\u201324 h<\/jats:sub>in the presence\/absence of taranabant 0.5 mg and 2 mg were 1.08 (0.99, 1.17) and 1.04 (0.98, 1.10), respectively. No significant differences in blood pressure and heart rate were observed with any treatment versus placebo. Coadministration of taranabant 0.5 mg, 1 mg, and 2 mg with phentermine was well tolerated with no pharmacokinetic interaction and did not result in meaningful changes in blood pressure or heart rate versus placebo.<\/jats:p>","DOI":"10.1177\/0091270009341651","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T21:25:39Z","timestamp":1253913939000},"page":"1228-1238","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid\u20101 Receptor (CB1R) Inverse Agonist"],"prefix":"10.1002","volume":"49","author":[{"given":"Carol","family":"Addy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Jumes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hankun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy O.","family":"Johnson\u2010Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chodakewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Obesity Fact Sheet","author":"World Health Organization (WHO).","year":"2008"},{"key":"e_1_2_5_3_2","volume-title":"Wechsler Adult Intelligence Scale\u2014Revised","year":"1981"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.59.2.2"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.1997.tb01261.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-200209000-00007"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/346561a0"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-6980(02)00060-6"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152706777452272"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00706.2002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.11.012"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm060996"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118737"},{"key":"e_1_2_5_14_2","first-page":"A326","article-title":"A two year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results","volume":"1021","author":"Gantz I","year":"2008","journal-title":"JACC"},{"key":"e_1_2_5_15_2","first-page":"S63","article-title":"Safety and efficacy of taranabant, a highly selective CB1\u2010R inverse agonist, over one year in obese and overweight patients with obesity\u2010related comorbidities","volume":"16","author":"Proietto J","year":"2008","journal-title":"Obesity"},{"key":"e_1_2_5_16_2","first-page":"S293","article-title":"A one\u2010year study to assess the efficacy, safety, and tolerability of taranabant, a highly selective CB1\u2010R inverse agonist, in overweight and obese patients with type 2 diabetes: 36\u2010week results","volume":"16","author":"Kipnes M","year":"2008","journal-title":"Obesity"},{"key":"e_1_2_5_17_2","first-page":"S89","article-title":"The efficacy and tolerability of taranabant, a cannabinoid receptor inverse agonist, over 24 weeks in obese patients","volume":"32","author":"Davidson MH","year":"2008","journal-title":"Int J Obes"},{"key":"e_1_2_5_18_2","first-page":"A147","article-title":"Taranabant plasma concentrations increased when co\u2010administered with ketoconazole or diltiazem","volume":"15","author":"Addy C","year":"2007","journal-title":"Obes Program Abstract Suppl"},{"key":"e_1_2_5_19_2","first-page":"A147","article-title":"Taranabant exhibits no clinically meaningful effect on the pharmacokinetic profile of midazolam","volume":"15","author":"Addy C","year":"2007","journal-title":"Obes Program Abstract Suppl"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199808000-00015"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0026-895X(25)15140-7","article-title":"N\u2010oxidation of phentermine to N\u2010hydroxyphentermine by a reconstituted cytochrome\u2010P\u2010450 oxidase system from rabbit liver","volume":"22","author":"Duncan JD","year":"1982","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008317591"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-200203000-00008"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(97)00029-0"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.564"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008314467"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009341651","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009341651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:58:05Z","timestamp":1739357885000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009341651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1177\/0091270009341651"],"URL":"https:\/\/doi.org\/10.1177\/0091270009341651","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}